Literature DB >> 21668738

Use of affinity-directed liquid chromatography-mass spectrometry to map the epitopes of a factor VIII inhibitor antibody fraction.

A E Griffiths1, W Wang, F K Hagen, P J Fay.   

Abstract

BACKGROUND: Neutralizing factor (F) VIII antibodies develop in approximately 30% of individuals with hemophilia A and show specificity to multiple sites in the FVIII protein.
METHODS: Reactive epitopes to an immobilized IgG fraction prepared from a high-titer, FVIII inhibitor plasma were determined after immuno-precipitation (IP) of tryptic and chymotryptic peptides derived from digests of the A1 and A2 subunits of FVIIIa and FVIII light chain. Peptides were detected and identified using highly sensitive liquid chromatography-mass spectrometry (LC-MS).
RESULTS: Coverage maps of the A1 subunit, A2 subunit and light chain represented 79%, 69% and 90%, respectively, of the protein sequences. Dot blots indicated that the inhibitor IgG reacted with epitopes contained within each subunit of FVIIIa. IP coupled with LC-MS identified 19 peptides representing epitopes from all FVIII A and C domains. The majority of peptides (10) were derived from the A2 domain. Three peptides mapped to the C2 domain, while two mapped to the A1 and A3 domains, and single peptides mapped to the a1 segment and C1 domain. Epitopes were typically defined by peptide sequences of < 12 residues.
CONCLUSIONS: IP coupled with LC-MS identified extensive antibody reactivity at high resolution over the entire functional FVIII molecule and yielded sequence lengths of < 15 residues. A number of the peptides identified mapped to known sequences involved in functionally important protein-protein and protein-membrane interactions.
© 2011 International Society on Thrombosis and Haemostasis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21668738      PMCID: PMC3154976          DOI: 10.1111/j.1538-7836.2011.04397.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  25 in total

Review 1.  Pathogenic antibodies to coagulation factors. Part one: factor VIII and factor IX.

Authors:  P Lollar
Journal:  J Thromb Haemost       Date:  2004-07       Impact factor: 5.824

2.  Factor VIIIa A2 subunit residues 558-565 represent a factor IXa interactive site.

Authors:  P J Fay; T Beattie; C F Huggins; L M Regan
Journal:  J Biol Chem       Date:  1994-08-12       Impact factor: 5.157

3.  Structure of human factor VIII.

Authors:  G A Vehar; B Keyt; D Eaton; H Rodriguez; D P O'Brien; F Rotblat; H Oppermann; R Keck; W I Wood; R N Harkins; E G Tuddenham; R M Lawn; D J Capon
Journal:  Nature       Date:  1984 Nov 22-28       Impact factor: 49.962

4.  Localization of epitopes for human factor VIII inhibitor antibodies by immunoblotting and antibody neutralization.

Authors:  D Scandella; M Mattingly; S de Graaf; C A Fulcher
Journal:  Blood       Date:  1989-10       Impact factor: 22.113

5.  Localization of a factor X interactive site in the A1 subunit of factor VIIIa.

Authors:  K A Lapan; P J Fay
Journal:  J Biol Chem       Date:  1997-01-24       Impact factor: 5.157

6.  The factor VIII Structure and Mutation Resource Site: HAMSTeRS version 4.

Authors:  G Kemball-Cook; E G Tuddenham; A I Wacey
Journal:  Nucleic Acids Res       Date:  1998-01-01       Impact factor: 16.971

7.  Some factor VIII inhibitor antibodies recognize a common epitope corresponding to C2 domain amino acids 2248 through 2312, which overlap a phospholipid-binding site.

Authors:  D Scandella; G E Gilbert; M Shima; H Nakai; C Eagleson; M Felch; R Prescott; K J Rajalakshmi; L W Hoyer; E Saenko
Journal:  Blood       Date:  1995-09-01       Impact factor: 22.113

8.  Residues 484-508 contain a major determinant of the inhibitory epitope in the A2 domain of human factor VIII.

Authors:  J F Healey; I M Lubin; H Nakai; E L Saenko; L W Hoyer; D Scandella; P Lollar
Journal:  J Biol Chem       Date:  1995-06-16       Impact factor: 5.157

9.  Inhibition of human factor VIIIa by anti-A2 subunit antibodies.

Authors:  P Lollar; E T Parker; J E Curtis; S L Helgerson; L W Hoyer; M E Scott; D Scandella
Journal:  J Clin Invest       Date:  1994-06       Impact factor: 14.808

10.  Epitope mapping of human factor VIII inhibitor antibodies by deletion analysis of factor VIII fragments expressed in Escherichia coli.

Authors:  D Scandella; S DeGraaf Mahoney; M Mattingly; D Roeder; L Timmons; C A Fulcher
Journal:  Proc Natl Acad Sci U S A       Date:  1988-08       Impact factor: 11.205

View more
  5 in total

1.  Epitope mapping of inhibitory antibodies targeting the C2 domain of coagulation factor VIII by hydrogen-deuterium exchange mass spectrometry.

Authors:  A M Sevy; J F Healey; W Deng; P C Spiegel; S L Meeks; R Li
Journal:  J Thromb Haemost       Date:  2013-12       Impact factor: 5.824

Review 2.  Hydrogen/deuterium exchange mass spectrometry applied to IL-23 interaction characteristics: potential impact for therapeutics.

Authors:  Roxana E Iacob; Stanley R Krystek; Richard Y-C Huang; Hui Wei; Li Tao; Zheng Lin; Paul E Morin; Michael L Doyle; Adrienne A Tymiak; John R Engen; Guodong Chen
Journal:  Expert Rev Proteomics       Date:  2015-02-24       Impact factor: 3.940

3.  Effects of replacement of factor VIII amino acids Asp519 and Glu665 with Val on plasma survival and efficacy in vivo.

Authors:  Matthew P Kosloski; Krithika A Shetty; Hironao Wakabayashi; Philip J Fay; Sathy V Balu-Iyer
Journal:  AAPS J       Date:  2014-06-17       Impact factor: 4.009

Review 4.  Engineering less immunogenic and antigenic FVIII proteins.

Authors:  Kathleen P Pratt
Journal:  Cell Immunol       Date:  2015-11-02       Impact factor: 4.868

5.  Six amino acid residues in a 1200 Å2 interface mediate binding of factor VIII to an IgG4κ inhibitory antibody.

Authors:  Jasper C Lin; Ruth A Ettinger; Jason T Schuman; Ai-Hong Zhang; Muhammad Wamiq-Adhami; Phuong-Cac T Nguyen; Shelley M Nakaya-Fletcher; Komal Puranik; Arthur R Thompson; Kathleen P Pratt
Journal:  PLoS One       Date:  2015-01-23       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.